Prelude Therapeutics Stock Buy Hold or Sell Recommendation
| PRLD Stock | USD 2.44 0.29 10.62% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Prelude Therapeutics is 'Strong Sell'. Macroaxis provides Prelude Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PRLD positions. Check out Prelude Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide. Note, we conduct extensive research on individual companies such as Prelude and provide practical buy, sell, or hold advice based on investors' constraints. Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Execute Prelude Therapeutics Buy or Sell Advice
The Prelude recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Prelude Therapeutics. Macroaxis does not own or have any residual interests in Prelude Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Prelude Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Fair | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Strong | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Prelude Therapeutics Trading Alerts and Improvement Suggestions
| Prelude Therapeutics is way too risky over 90 days horizon | |
| Prelude Therapeutics appears to be risky and price may revert if volatility continues | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from benzinga.com: Tenaya Stock Plunges After 60 Million Equity Offering |
Prelude Therapeutics Returns Distribution Density
The distribution of Prelude Therapeutics' historical returns is an attempt to chart the uncertainty of Prelude Therapeutics' future price movements. The chart of the probability distribution of Prelude Therapeutics daily returns describes the distribution of returns around its average expected value. We use Prelude Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Prelude Therapeutics returns is essential to provide solid investment advice for Prelude Therapeutics.
| Mean Return | 2.33 | Value At Risk | -12.9 | Potential Upside | 16.44 | Standard Deviation | 21.39 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Prelude Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Prelude Stock Institutional Investors
| Shares | Royal Bank Of Canada | 2025-06-30 | 2.8 K |
Prelude Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (263.8M) | 81.7M | (41.0M) | 90.2M | 103.7M | 108.9M | |
| Change In Cash | (182.4M) | (1.2M) | (5.3M) | (12.8M) | (11.5M) | (11.0M) | |
| Free Cash Flow | (85.9M) | (86.7M) | (110.6M) | (103.7M) | (93.3M) | (98.0M) | |
| Depreciation | 915K | 1.3M | 1.2M | 1.8M | 2.0M | 2.1M | |
| Other Non Cash Items | 2.7M | 4.3M | (1.5M) | (3.0M) | (2.7M) | (2.6M) | |
| Capital Expenditures | 2.3M | 3.0M | 3.5M | 764K | 878.6K | 834.7K | |
| Net Income | (111.7M) | (115.4M) | (121.8M) | (127.2M) | (114.5M) | (120.2M) | |
| End Period Cash Flow | 35.9M | 34.6M | 29.3M | 16.5M | 14.9M | 14.1M | |
| Change To Netincome | 856K | 5.6M | 23.6M | 29.5M | 33.9M | 35.6M |
Prelude Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Prelude Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Prelude Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Prelude stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.37 | |
β | Beta against Dow Jones | -0.64 | |
σ | Overall volatility | 22.23 | |
Ir | Information ratio | 0.11 |
Prelude Therapeutics Volatility Alert
Prelude Therapeutics is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Prelude Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Prelude Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Prelude Therapeutics Fundamentals Vs Peers
Comparing Prelude Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Prelude Therapeutics' direct or indirect competition across all of the common fundamentals between Prelude Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Prelude Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Prelude Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Prelude Therapeutics to competition |
| Fundamentals | Prelude Therapeutics | Peer Average |
| Return On Equity | -1.04 | -0.31 |
| Return On Asset | -0.52 | -0.14 |
| Operating Margin | (3.14) % | (5.51) % |
| Current Valuation | 134.52 M | 16.62 B |
| Shares Outstanding | 50.02 M | 571.82 M |
| Shares Owned By Insiders | 9.93 % | 10.09 % |
| Shares Owned By Institutions | 54.47 % | 39.21 % |
| Number Of Shares Shorted | 1.28 M | 4.71 M |
| Price To Book | 2.93 X | 9.51 X |
| Price To Sales | 16.34 X | 11.42 X |
| Revenue | 7 M | 9.43 B |
| Gross Profit | 10.5 M | 27.38 B |
| EBITDA | (137.94 M) | 3.9 B |
| Net Income | (127.17 M) | 570.98 M |
| Cash And Equivalents | 246.3 M | 2.7 B |
| Cash Per Share | 5.19 X | 5.01 X |
| Total Debt | 18.02 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 15.73 X | 2.16 X |
| Book Value Per Share | 0.77 X | 1.93 K |
| Cash Flow From Operations | (102.89 M) | 971.22 M |
| Short Ratio | 2.95 X | 4.00 X |
| Earnings Per Share | (1.47) X | 3.12 X |
| Price To Earnings To Growth | (0.09) X | 4.89 X |
| Target Price | 4.0 | |
| Number Of Employees | 131 | 18.84 K |
| Beta | 1.06 | -0.15 |
| Market Capitalization | 171.62 M | 19.03 B |
| Total Asset | 175.51 M | 29.47 B |
| Retained Earnings | (583.56 M) | 9.33 B |
| Working Capital | 110.25 M | 1.48 B |
| Net Asset | 175.51 M |
Note: Disposition of 9375 shares by Huang Jane of Prelude Therapeutics subject to Rule 16b-3 [view details]
Prelude Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Prelude . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 65319.78 | |||
| Daily Balance Of Power | (0.69) | |||
| Rate Of Daily Change | 0.89 | |||
| Day Median Price | 2.58 | |||
| Day Typical Price | 2.53 | |||
| Price Action Indicator | (0.29) | |||
| Period Momentum Indicator | (0.29) | |||
| Relative Strength Index | 27.11 |
About Prelude Therapeutics Buy or Sell Advice
When is the right time to buy or sell Prelude Therapeutics? Buying financial instruments such as Prelude Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Prelude Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long/short ETFs Thematic Idea Now
Long/short ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Long/short ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long/short ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Prelude Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.